Klingenstein Fields & Co. LLC cut its stake in Becton, Dickinson and Company (NYSE:BDX) by 14.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,000 shares of the medical instruments supplier’s stock after selling 1,000 shares during the period. Klingenstein Fields & Co. LLC’s holdings in Becton, Dickinson and were worth $1,176,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the stock. Almanack Investment Partners LLC. purchased a new stake in Becton, Dickinson and during the first quarter valued at about $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its position in Becton, Dickinson and by 55.8% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after buying an additional 240 shares during the period. Parkside Financial Bank & Trust boosted its position in Becton, Dickinson and by 8.1% during the second quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock valued at $133,000 after buying an additional 51 shares during the period. Harfst & Associates Inc. boosted its position in Becton, Dickinson and by 46.4% during the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after buying an additional 221 shares during the period. Finally, Financial Architects Inc boosted its position in Becton, Dickinson and by 8.0% during the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after buying an additional 54 shares during the period. Institutional investors own 86.71% of the company’s stock.

Several research firms have issued reports on BDX. Barclays PLC restated an “equal weight” rating and set a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. BidaskClub lowered shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “sell” rating to a “hold” rating in a research report on Friday, October 20th. Stifel Nicolaus restated a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $213.00 price target on shares of Becton, Dickinson and in a research report on Tuesday, September 12th. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $213.47.

TRADEMARK VIOLATION WARNING: “Klingenstein Fields & Co. LLC Cuts Position in Becton, Dickinson and Company (BDX)” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/11/klingenstein-fields-co-llc-cuts-position-in-becton-dickinson-and-company-bdx.html.

Becton, Dickinson and Company (BDX) opened at $219.23 on Friday. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $225.23. The stock has a market cap of $51,083.79, a PE ratio of 23.65, a P/E/G ratio of 1.76 and a beta of 1.04. The company has a quick ratio of 5.01, a current ratio of 5.56 and a debt-to-equity ratio of 1.48.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The company had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.14 billion. During the same period in the prior year, the firm earned $2.12 earnings per share. Becton, Dickinson and’s revenue was down 2.0% on a year-over-year basis. analysts anticipate that Becton, Dickinson and Company will post 10.63 EPS for the current year.

In related news, insider Gary M. Cohen sold 15,512 shares of the stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the transaction, the insider now directly owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Stephen Sichak sold 11,787 shares of the stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the completion of the transaction, the insider now directly owns 14,038 shares of the company’s stock, valued at $2,814,057.48. The disclosure for this sale can be found here. Over the last three months, insiders sold 60,650 shares of company stock valued at $12,223,970. 1.40% of the stock is owned by insiders.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.